Abilify

Since the passing of a recent deadline to reach a global settlement in nearly 1,700 Abilify lawsuits (up from the 22 cases originally consolidated in 2016), counsel for defendants Otsuka Pharmaceuticals and Bristol-Meyer Squibb (BSM) and those for the plaintiffs have been working overtime to prepare for the test...

As of April of 2018, the were over 800 lawsuits pending against Otsuka Pharmaceuticals and its U.S. partner, Bristol-Meyer Squibb (BMS) over the psychoactive medication Abilify (aripiprizole).  Plaintiffs allege that the drugmakers failed to warn patients and doctors about side effects that cause compulsive, uncontrollable behaviors, particularly gambling.  Another alleged side...

A six-year legal battle has finally ended for drugmakers Bristol-Meyer Squibb (BMS) and Otsuka as a judicial panel recently made a 2 to 1 decision not to revive a whistleblower lawsuit filed by two former employees.In U.S. v. Bristol Meyers Squibb Co., the Sixth Circuit ruled that the...

A recent report from Allied Market Research has provided some news that is giving CEOs and shareholders in major pharmaceutical companies some reason to celebrate. Because of the rise in the number of patients suffering mental illness, primarily schizophrenia, the market for neuroleptic and anti-psychotic medications such as Abilify...

For some time, it has been known that the anti-depressant drug Abilify causes people who take it to behave in reckless, impulsive ways. In these situations, manufacturers of such harmful prescription medications argue that the benefits of the product outweigh the risks, often citing self-funded research studies. However, a...

Undeterred by a growing number of lawsuits over the antipsychotic medication Abilify, drugmaker Otsuka Pharmaceutical Company and its partners at Bristol-Meyers continue to seek new markets, promoting the drug for off-label uses ranging from autism to dementia and eating disorders.Bristol-Meyers even wound up paying out a $19.5 million...

In 1999, the Center for Science and Law reported that a large number of anti-psychotic medications were being given to juvenile offenders – regardless of whether or not they had actually been diagnosed with a mental disorder. It was described as “a mere replacement of the old-fashioned use of...

In 2009, the FDA approved Abilify (aripiprazole) for treating irritability in autistic children and youth up to age 17. In a press release issued at the time, manufacturer Bristol-Meyers Squibb stated that Abilify – normally used to treat bipolar disorder, schizophrenia and depression – should be used in conjunction...

Can Abilify, demonstrated to cause uncontrollable, impulsive and destructive behavior, also cause the user to engage in criminal behavior? A former gun-runner and convicted fraudster believes so – and is going to court in order to prove it. Many people don't remember the name Efraim Diveroli today, but his life...

It is being established that the anti-psychotic medication Abilify (aripiprazole) has the potential to cause irrational, compulsive behaviors in patients who take it. One of the tragedies is that neither patients nor physicians had any idea of the connection – at least in the U.S. One thing is certain:...